NEUROCRINE BIOSCIENCES INC (NBIX)       101.36  +0.79 (+0.79%)

101.36  +0.79 (+0.79%)

US64125C1099 - Common Stock - After market: 101.36 0 (0%)

News Image
4 days ago - Investor's Business Daily

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

Eli Lilly leads medical stocks setting up and showing relative strength.

News Image
9 days ago - BusinessInsider

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Data on Sustained Treatment Response at Psych Congress 2022

SAN DIEGO, Sept. 19, 2022  /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data demonstrating sus...

News Image
11 days ago - Investor's Business Daily

S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms

Devon Energy leads this weekend's watch list of stocks in a tough market.

News Image
13 days ago - Investor's Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

News Image
13 days ago - BusinessInsider

Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress

SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstr...

News Image
13 days ago - BusinessInsider

Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress

SAN DIEGO, Sept. 15, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapo...

News Image
13 days ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present Study Findings on Evolving Tardive Dyskinesia Education Needs of Physicians at the 2022 MDS International Congress

/PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the presentation of survey findings demonstrating the need for education on...

News Image
13 days ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences Presents New Post-Hoc Analysis of ONGENTYS® (opicapone) Capsules Effect on COMT Activity at the 2022 MDS International Congress

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today will present data on the effects of ONGENTYS® (opicapone) capsules on...

News Image
16 days ago - Neurocrine Biosciences, Inc.

Parkinson & Movement Disorder (PMD) Alliance and Neurocrine Biosciences Announce New Survey Results Revealing the Significant Impact OFF Time Has on People with Parkinson's Disease and Their Care Partners

/PRNewswire/ -- Parkinson & Movement Disorder (PMD) Alliance, in partnership with Neurocrine Biosciences (Nasdaq: NBIX), a leading neuroscience-focused...

News Image
22 days ago - BusinessInsider

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

SAN DIEGO, Sept. 6, 2022 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthc...

News Image
22 days ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Morgan Stanley 20th Annual Global Healthcare Conference at 10:35 a.m. Eastern...

News Image
25 days ago - Investor's Business Daily

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks showing resilience.

News Image
2 months ago - Investor's Business Daily

Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review

The Nasdaq and small caps rose while the S&P 500 is hitting resistance.

News Image
2 months ago - BusinessInsider

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

INGREZZA® (valbenazine) Second Quarter Net Product Sales of $350 MillionINGREZZA® (valbenazine) 2022 Net Product Sales Guidance Raised to $1.35 - ...

News Image
2 months ago - Investor's Business Daily

Neurocrine Biosciences Shelves Key Drug; Will It Overshadow The Earnings Beat?

Neurocrine says the essential tremor drug didn't hit its goals in a key study.

News Image
2 months ago - Neurocrine Biosciences, Inc.

Neurocrine Biosciences Reports Second Quarter 2022 Financial Results and Raises 2022 INGREZZA Sales Guidance

/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2022 and raised net...

News Image
2 months ago - Investor's Business Daily

Dow Jones Giant Amgen Leads 5 Stocks To Watch Near Buy Points

Dow Jones giant Amgen headlines five stocks to watch setting near buy points or key support levels that may offer early entries.

News Image
3 months ago - BusinessInsider

Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2022 Financial Results

Conference Call and Webcast Scheduled for Thursday, August 4SAN DIEGO, July 14, 2022/PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) an...